CompletedNot Applicable

Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair

8,325 participantsStarted 2003-01-01

Plain-language summary

This study was a target trial emulation using the National Health Claims database established by the Korean National Health Insurance Service (K-NHIS). 8,325 patients were included.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All patients who underwent EVAR for AAA and were successfully discharged Exclusion Criteria: * Patients who had experienced a myocardial infarction * Patients who had experienced a stroke * Patients who had experienced percutaneous coronary intervention * Patients who had history of peripheral disease * Patients who had major bleeding event within 1 year of admission * Those prescribed non-vitamin K antagonist oral anticoagulant or warfarin * Patients who did not prescribe any antiplatelet therapy

What they're measuring

Major adverse cardiac and cerebrovascular events (MACCE)

Timeframe: 1 year after EVAR

Major or clinically relevant non-major bleeding

Timeframe: 1 year after EVAR

Re-intervention or surgery for AAAs

Timeframe: 1 year after EVAR

Trial details

NCT IDNCT06876727

SponsorSamsung Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-09-30

View on ClinicalTrials.gov More Abdominal Aortic Aneurysms (AAA) trials